Bio-Path Holdings Provides 2025 Clinical and Operational Update
January 10, 2025 07:00 ET
|
Bio-Path Holdings, Inc.
Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path...
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
December 19, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
December 11, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic Program and Discontinues Enrollment...
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
November 15, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a...
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
November 08, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
October 10, 2024 17:24 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and...
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
October 08, 2024 20:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and...
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
October 08, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings Announces Publication in Biomedicines
September 16, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
Manuscript Highlights Therapeutic Potential of BP1003 in Variety of Cancers Marks Company’s Twenty-Second Peer-Reviewed Publication in Support of its DNAbilize® Technology HOUSTON, Sept. 16, 2024 ...
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...